Top Markets
#1 MowCat MowCat +367.01%
#2 龙虾 (Lobster) 龙虾 (Lobster) +64.29%
#3 SODAX SODAX +47.33%
#4 Cortex Cortex +33.11%
#5 DexNet DexNet +23.19%
#6 OpenEden OpenEden +20.03%
#7 MANTRA MANTRA +18.18%
#8 Akedo Akedo +17.03%
#9 Magma Finance Magma Finance +16.03%
#10 wojak wojak +15.65%
Coin of the day
MowCat MowCat
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Biotest AG Biotest AG

Biotest AG

BIO
Classement en actions #7311
Biotest AG is a German biopharmaceutical company focused on the global... Biotest AG is a German biopharmaceutical company focused on the global development, manufacturing, and commercialization of biological medications. The firm organizes its activities into the Therapy, Plasma & Services, and Other segments. Its product portfolio addresses critical needs in hematology, clinical immunology, and intensive care medicine. Among its offerings are treatments for hemophilia A (such as Haemoctin and Vihuma) and hemophilia B (like Haemonine), covering both acute care and prevention. Biotest also provides therapies for various viral infections, including cytomegalovirus (Cytotect CP), hepatitis B (Fovepta, Hepatect, Zutectra), and varicella zoster (Varitect). Additionally, its products, such as Intratect and IgG Next Generation, are utilized for primary and secondary immune deficiencies, autoimmune disorders, and certain neurological conditions. The company further supplies solutions to manage circulating blood volume (Albiomin, Biseko), address clotting factor deficiencies (Cofact, Fibrinogen), and combat serious infections like community-acquired pneumonia and COVID-19 (Trimodulin), as well as general bacterial infections (Pentaglobin). Established in 1946 as Biotest Serum-Institut GmbH, the company adopted its current name, Biotest Aktiengesellschaft, in 1986. Headquartered in Dreieich, Germany, Biotest Aktiengesellschaft has been operating as a subsidiary of Grifols, S.A. since January 21, 2022.
Prix de l'action
$47.45
Dernière synchronisation: 2026-05-13
Capitalisation boursière
$1.63B
Changement (1 jour)
2.04%
Changement (1 an)
3.15%
Pays
DE
Échange Biotest AG (BIO)

Catégorie

Healthcare
Revenus pour Biotest AG (BIO)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Biotest AG, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Biotest AG de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH